Contrairement aux affirmations à l’emporte-pièce de...
Remdesivir : Covid-19 patients recovering quickly after getting experimental drug - CNN
... et Bret Stephens (New York times)...
Opinion | The Story of Remdesivir - The New York Times
...les résultats partiels d’une étude en cours (connus grâce à une « fuite »- qui a fait bondir la valeur en bourse de la compagnie pharmaceutique mère...) ne prouvent nullement l’efficacité du #remdesivir, comme expliqué ci-dessous :
What’s Happening With Remdesivir ? | In the Pipeline
But now that it’s out there, let’s talk about what’s in the leak. Gilead stock jumped like a spawning salmon in after-market trading on this, and one of the reasons was that that 113 of the 125 patients were classed as having “severe disease”. People ran with the idea that these must have been people on ventilators who were walking out of the hospital, but that is not the case. As AndyBiotech pointed out on Twitter, all you had to do was read the trial’s exclusion criteria: patients were not even admitted into the trial if they were on mechanical ventilation. Some will have moved on to ventilation during the trial, but we don’t know how many (the trial protocol has these in a separate group).
Note also that this trial is open-label ; both doctors and patients know who is getting what, and note the really key point: there is no control arm . This is one of the trials mentioned in this post on small-molecule therapies as being the most likely to read out first, but it’s always been clear that the tradeoff for that speed is rigor. The observational paper that was published on remdesivir in the NEJM had no controls either, of course, and that made it hard to interpret. Scratch that, it made it impossible to interpret. It will likely be the same with this trial – the comparison is between a five-day course of remdesivir and a ten-day course, and the primary endpoint is the odds ratio for improvement between the two groups.
Et ce d’autant plus que la « fuite » survient juste après l’annonce de l’arrêt avant-terme de deux études chinoises sur le remdesivir (ce qui avait eu un mauvais effet sur la cotation en bourse...)
More Small Molecule Clinical Data Against Covid-19, As of April 16 | In the Pipeline
I refer to trials of Gilead’s remdesivir in China, one for moderate cases and one for severe ones, both of which were updated yesterday to “suspended” on ClinicalTrials.gov. That took people by surprise, and Gilead’s stock dropped in response.